Welcome to our dedicated page for Freenome SEC filings (Ticker: PCSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Freenome's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Freenome's regulatory disclosures and financial reporting.
Freenome, Inc. reported a Form 3 insider filing for director Nuechterlein Carole, providing an initial statement of beneficial ownership. The report shows no buy or sell transactions, no derivative positions, and no reported holdings, and notes an Exhibit 24 Power of Attorney authorizing filings on her behalf.
Freenome, Inc. identifies Ann Catherine Costello as a director in an initial statement of beneficial ownership of securities. The report shows no listed equity holdings, no derivative positions, and no reported transactions by the reporting person. It also references an Exhibit 24 Power of Attorney.
Freenome, Inc. director Douglas M. Van Oort reports initial beneficial ownership of 20,867 shares of Common Stock held directly, plus three stock options covering 9,588, 32,147 and 6,484 shares of Common Stock at exercise prices of $14.00 and $8.45, expiring in 2035, with specified vesting schedules and a potential automatic reduction of the $14.00 exercise price upon certain events.
Freenome, Inc. disclosed the initial equity holdings of its Chief Financial Officer, Le Linh H., who directly holds 64,294 shares of Common Stock and a stock option for 128,587 shares of Common Stock at a $14.00 exercise price, expiring May 28, 2035.
Footnotes state that 25% of the option shares vest on May 19, 2026, with the rest in 36 equal monthly installments, subject to continued service, and that the exercise price will be automatically reduced to $8.45 if certain events occur.
Freenome, Inc. reports that Chief Executive Officer Elliott Aaron Matthew beneficially owns 417,896 shares of Common Stock directly as of July 20, 2026. He also holds a stock option to acquire 417,895 shares of Common Stock at an exercise price of $14.00 per share, expiring on May 28, 2035. According to the terms, 25% of the option vests on April 1, 2026, with the remainder vesting in 36 equal monthly installments, subject to his continued service, and the option’s exercise price will be automatically reduced to $8.45 upon the occurrence of certain specified events.
Deepika Pakianathan, a director of Freenome, Inc., reports beneficial ownership of 13,918 shares of Common Stock held directly, plus several stock option awards over additional Common Stock. These options cover 14,144, 6,365, 3,359, 7,359, 9,588 and 6,484 underlying shares with exercise prices between $8.45 and $18.24, expiring from 2031 through 2035. Some options are fully vested, while others vest in 48 equal monthly installments starting June 28, 2023 or March 2, 2024, and certain options may have their exercise price automatically reduced to $8.45 upon specified events.
Freenome, Inc. director Scott Randal W. filed an initial statement of beneficial ownership, reporting common stock and stock option positions. He holds 12235.0000 Freenome common shares directly and 91969.0000 shares indirectly through Thinking Bench Capital, LLC, for which he disclaims beneficial ownership except for any pecuniary interest. He also reports several stock options over common stock, including an option over 71476.0000 shares at an exercise price of $2.83 expiring in 2028 and additional smaller grants with exercise prices from $8.45 to $18.24, some fully vested and others vesting in 48 equal monthly installments beginning in 2023 or 2024.
Freenome, Inc. reports that Chief Scientific Officer Lin Cheng-Ho Jimmy holds 410,154 shares of Common Stock directly, plus several stock options to acquire additional Common Stock at exercise prices ranging from 4.8500 to 18.2400, with expirations between 2029 and 2035. Certain options are fully vested, while others vest in monthly installments under service-based schedules; no new purchases or sales are reported.
Freenome, Inc. Chief Product Officer Ennis Riley Charles files an initial ownership report detailing his holdings of common stock and stock options. He reports direct ownership of common stock and additional shares held indirectly by the Riley Ennis Irrevocable Trust, for which he disclaims beneficial ownership except for any pecuniary interest.
The filing lists several stock options (rights to buy common stock) with exercise prices ranging from $4.8500 to $18.2400 and expirations between 2030 and 2035, including options that are fully vested and others that vest in monthly installments. One option’s exercise price will be automatically reduced to $8.45 upon certain events.
Freenome, Inc. reports that investment entities affiliated with Andreessen Horowitz have filed a Schedule 13G disclosing their beneficial ownership of the company’s common stock. The filing covers multiple Delaware limited partnerships and LLCs, as well as Marc L. Andreessen and Benjamin A. Horowitz.
The positions include 3,327,525 shares held by AH Bio Fund I, L.P., 1,038,814 shares held by Andreessen Horowitz LSV Fund II, L.P., 6,207 shares held by CLF Partners, LP, and 1,199,053 shares held by AH Parallel Fund IV, L.P., each with sole voting and dispositive power through their respective general partners. Based on 107,446,814 shares of common stock outstanding as of July 20, 2026, Marc Andreessen and Ben Horowitz are each reported as beneficially owning 5,571,599 shares, or 5.2% of the common stock, through their managing member roles in the general partner entities.